195 related articles for article (PubMed ID: 38849950)
1. Alzheimer's disease and drug delivery across the blood-brain barrier: approaches and challenges.
Iqbal I; Saqib F; Mubarak Z; Latif MF; Wahid M; Nasir B; Shahzad H; Sharifi-Rad J; Mubarak MS
Eur J Med Res; 2024 Jun; 29(1):313. PubMed ID: 38849950
[TBL] [Abstract][Full Text] [Related]
2. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease.
Yin T; Yang L; Liu Y; Zhou X; Sun J; Liu J
Acta Biomater; 2015 Oct; 25():172-83. PubMed ID: 26143603
[TBL] [Abstract][Full Text] [Related]
3. The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview.
Jakki SL; Senthil V; Yasam VR; Chandrasekar MJN; Vijayaraghavan C
Curr Drug Targets; 2018; 19(2):155-169. PubMed ID: 28606049
[TBL] [Abstract][Full Text] [Related]
4. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
[TBL] [Abstract][Full Text] [Related]
5. Recent Trends in Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's Disease.
Mazahir F; Yadav AK
CNS Neurol Disord Drug Targets; 2023; 22(4):477-499. PubMed ID: 35450536
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.
Banks WA
Adv Drug Deliv Rev; 2012 May; 64(7):629-39. PubMed ID: 22202501
[TBL] [Abstract][Full Text] [Related]
7. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.
Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419
[TBL] [Abstract][Full Text] [Related]
8. Liposome delivery systems for the treatment of Alzheimer's disease.
Ross C; Taylor M; Fullwood N; Allsop D
Int J Nanomedicine; 2018; 13():8507-8522. PubMed ID: 30587974
[TBL] [Abstract][Full Text] [Related]
9. The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery.
Sharma HS; Castellani RJ; Smith MA; Sharma A
Int Rev Neurobiol; 2012; 102():47-90. PubMed ID: 22748826
[TBL] [Abstract][Full Text] [Related]
10. Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers.
Tonda-Turo C; Origlia N; Mattu C; Accorroni A; Chiono V
Curr Med Chem; 2018; 25(41):5755-5771. PubMed ID: 29473493
[TBL] [Abstract][Full Text] [Related]
11. Targeted drug delivery across the blood brain barrier in Alzheimer's disease.
Rocha S
Curr Pharm Des; 2013; 19(37):6635-46. PubMed ID: 23621533
[TBL] [Abstract][Full Text] [Related]
12. [Blood-brain barrier and Alzheimer's disease].
Kuwahara H; Nishida Y; Yokota T
Brain Nerve; 2013 Feb; 65(2):145-51. PubMed ID: 23399672
[TBL] [Abstract][Full Text] [Related]
13. Regulation of neuroinflammation in Alzheimer's disease via nanoparticle-loaded phytocompounds with anti-inflammatory and autophagy-inducing properties.
Nayak V; Patra S; Rout S; Jena AB; Sharma R; Pattanaik KP; Singh J; Pandey SS; Singh RP; Majhi S; Singh KR; Kerry RG
Phytomedicine; 2024 Jan; 122():155150. PubMed ID: 37944239
[TBL] [Abstract][Full Text] [Related]
14. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
[TBL] [Abstract][Full Text] [Related]
15. A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies.
Wasielewska JM; Chaves JCS; Johnston RL; Milton LA; Hernández D; Chen L; Song J; Lee W; Leinenga G; Nisbet RM; Pébay A; Götz J; White AR; Oikari LE
Theranostics; 2022; 12(16):6826-6847. PubMed ID: 36276649
[No Abstract] [Full Text] [Related]
16. Dual-functional nanoparticles for precise drug delivery to Alzheimer's disease lesions: Targeting mechanisms, pharmacodynamics and safety.
Zheng X; Zhang C; Guo Q; Wan X; Shao X; Liu Q; Zhang Q
Int J Pharm; 2017 Jun; 525(1):237-248. PubMed ID: 28432017
[TBL] [Abstract][Full Text] [Related]
17. Current Insights of Nanocarrier-Mediated Gene Therapeutics to Treat Potential Impairment of Amyloid Beta Protein and Tau Protein in Alzheimer's Disease.
Jain U; Johari S; Srivastava P
Mol Neurobiol; 2024 Apr; 61(4):1969-1989. PubMed ID: 37831361
[TBL] [Abstract][Full Text] [Related]
18. Dendrimeric Poly(Epsilon-Lysine) Delivery Systems for the Enhanced Permeability of Flurbiprofen across the Blood-Brain Barrier in Alzheimer's Disease.
Al-Azzawi S; Masheta D; Guildford AL; Phillips G; Santin M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340406
[TBL] [Abstract][Full Text] [Related]
19. Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration.
Kuo YC; Chen CL; Rajesh R
Acta Biomater; 2019 Mar; 87():207-222. PubMed ID: 30716553
[TBL] [Abstract][Full Text] [Related]
20. Nose-to-brain drug delivery for the treatment of Alzheimer's disease: current advancements and challenges.
A P; Agrawal M; Dethe MR; Ahmed H; Yadav A; Gupta U; Alexander A
Expert Opin Drug Deliv; 2022 Jan; 19(1):87-102. PubMed ID: 35040728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
